Back to directory
Shirisha Jonnalagadda
Shirisha Jonnalagadda
Assistant Professor, Addl Pay Non-Instructional
- Department(s): Chemistry
- Office Location: Upham Hall 259
- Phone: (262) 472-5121
- Email: jonnalas@uww.edu
Education
PhD Integrated Biosciences University of Minnesota, MN
MS Chemistry University of Minnesota Duluth, MN
MS Chemistry National Institute of Technology Warangal, India
BS Chemistry, Physics & Mathematics Kakatiya University, India
Professional experience
2023-current Assistant Professor in Organic Chemistry, University of Wisconsin-Whitewater
2021-2023 Post-doctoral Research Associate, University of Nebraska Medical Center, Omaha
2019-2020 Post-doctoral Research Associate, Texas Tech University Health Sciences Center, Lubbock
2010-2019 Graduate Research Assistant, University of Minnesota, Duluth
2009-2010 Junior Research Scientist, University of Minnesota, Duluth
Research interests
I have expertise in drug design and development, organic synthesis, medicinal chemistry, and pharmaceutical sciences. As a part of my Ph.D. thesis, I worked on the synthesis and evaluation of novel cyanocinnamic acid-based small molecules as monocarboxylate transporter (MCT) inhibitors, which included the synthesis of numerous drug candidates, in vitro and in vivo studies and the development of several lead molecules for cancer treatment. My post-doctoral research at Texas Tech University Health Sciences Center, Lubbock, primarily focused on DNA repair mechanisms, RAD6 inhibition, and the role of LYL1 in ovarian cancer. My second postdoctoral studies included the synthesis of small non-peptidomimetic molecules based on the pyridine-piperidine template for the activation of neurolysin as a potential treatment for ischemic stroke. I was also involved in the biological evaluation of VEGFR2 inhibitors, AKR1C3 inhibitors, and tricyclic ketals. My research work as a graduate student and postdoctoral fellow lays the foundation for my future research. My plan for future research at UWW is to design and synthesize new drug candidates to establish more potent and less toxic molecules with minimal side effects for the treatment of various cancers and other diseases.
Professional experience
2023-current Assistant Professor in Organic Chemistry, University of Wisconsin-Whitewater
2021-2023 Post-doctoral Research Associate, University of Nebraska Medical Center, Omaha
2019-2020 Post-doctoral Research Associate, Texas Tech University Health Sciences Center, Lubbock
2010-2019 Graduate Research Assistant, University of Minnesota, Duluth
2009-2010 Junior Research Scientist, University of Minnesota, Duluth
Research interests
I have expertise in drug design and development, organic synthesis, medicinal chemistry, and pharmaceutical sciences. As a part of my Ph.D. thesis, I worked on the synthesis and evaluation of novel cyanocinnamic acid-based small molecules as monocarboxylate transporter (MCT) inhibitors, which included the synthesis of numerous drug candidates, in vitro and in vivo studies and the development of several lead molecules for cancer treatment. My post-doctoral research at Texas Tech University Health Sciences Center, Lubbock, primarily focused on DNA repair mechanisms, RAD6 inhibition, and the role of LYL1 in ovarian cancer. My second postdoctoral studies included the synthesis of small non-peptidomimetic molecules based on the pyridine-piperidine template for the activation of neurolysin as a potential treatment for ischemic stroke. I was also involved in the biological evaluation of VEGFR2 inhibitors, AKR1C3 inhibitors, and tricyclic ketals. My research work as a graduate student and postdoctoral fellow lays the foundation for my future research. My plan for future research at UWW is to design and synthesize new drug candidates to establish more potent and less toxic molecules with minimal side effects for the treatment of various cancers and other diseases.
Teaching
Spring 2024 CHEM 252 Organic Chemistry II
Spring 2024 CHEM 261 Organic Chemistry Laboratory
Spring 2024 CHEM 262 Organic Chemistry Intermediate Laboratory
Fall 2024 CHEM 251 Organic Chemistry I
Fall 2024 CHEM 261 Organic Chemistry Laboratory
Fall 2024 CHEM 102 General Chemistry Laboratory
Sum 2024 CHE 352 Organic Chemistry Bootcamp Laboratory
Spring 2024 CHEM 252 Organic Chemistry II
Spring 2024 CHEM 261 Organic Chemistry Laboratory
Spring 2024 CHEM 102 General Chemistry Laboratory
Fall 2023 CHEM 251 Organic Chemistry I
Fall 2023 CHEM 261 Organic Chemistry Laboratory
Fall 2023 CHEM 102 General Chemistry Laboratory
Office hours Spring 2025
MTR 11:00 AM to 12:30 PM in UH259
or by appointment
Selected publications
- Carmona AV*, Jonnalagadda S*, Case, A.M., Maddeboina K, Jonnalagadda SK, Dow LF, Duan L, Penning TM, Trippier PC, “Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader” Commun Chem, 2024, 7:95.
- Huwaimel BI, Jonnalagadda SK, Jonnalagadda S, Kumari S, Nocentini A, Supuran CT, Trippier PC. “Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold” Drug Dev Res, 2023, 1-22.
- Huwaimela BI, Jonnalagadda SK, Jonnalagadda S, Zahra FT, Nocentini A, Supuran CT, Mikelis CM, Trippier PC. “Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation” Bioorg Med Chem, 2022, 67:116805.
- Jonnalagadda SK, Huwaimel B, Jonnalagadda S, Garrison JC, Trippier PC “Access to highly strained tricyclic ketals derived from coumarins” J Org Chem, 2022, 87(6):4476-4482.
- Nelson GL, Ronayne CT, Solano LN, Jonnalagadda SK, Jonnalagadda S, Schumacher TJ, Gardner ZS, Palle H, Mani C, Rumbley J, Mereddy VR “Synthesis and biological evaluation of N, N-dialkylcarboxy coumarin-NO donor conjugates as potential anticancer agents” Med. Chem. Lett., 2021, 52:128411.
- Reedy M, Jonnalagadda S, and Palle K “Case report: Intra-tumoral vaccinations of quadrivalent HPV-L1 peptide vaccine with topical TLR-7 agonist following recurrence after radiation therapy: Complete resolution of HPV-HR-associated gynecologic squamous cell carcinomas in two patients.” Pathology & Oncology Research 2021, 27:1609922.
- Jonnalagadda SK, Wielenberg K, Ronayne CT, Jonnalagadda S, Kiprof K, Jonnalagadda SC, Mereddy V. “Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents” Med. Chem. Lett., 2020, 30(14):127259.
- Jonnalagadda S, Jonnalagadda SK, Ronayne CT, Nelson GL, Solano LN, Rumbley J, Holy J, Mereddy VR, Drewes LR, “Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors” Oncotarget, 2019, 10(24):2355-2368.
- Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K, “Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple negative breast cancer cells" Breast Cancer Res, 2019, 21(1):104.